Viewing Study NCT01569750

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 5:08 PM
Ignite Modification Date: 2026-01-27 @ 6:43 AM
Study NCT ID: NCT01569750
Status: COMPLETED
Last Update Posted: 2017-08-22
First Post: 2012-03-30
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: A Study Combining Ibrutinib With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With CD20-Positive B-Cell Non Hodgkin Lymphoma
Sponsor: Janssen Research & Development, LLC
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None CD20-positive B-cell Non-Hodgkin Lymphoma View
Keywords:

Keywords

Keyword Brief Keyword Text View
None CD20-positive B-cell non-Hodgkin lymphoma View
None Diffuse large B-cell lymphoma View
None Mantle cell lymphoma View
None Follicular lymphoma View
None Ibrutinib View
None R-CHOP View
None Rituximab View
None Cyclophosphamide View
None Doxorubicin View
None Vincristine View
None Prednisone View